Nanoparticles have been proposed as carriers for drugs, genes and therapies to treat various diseases 1, 2 . Many strategies have been developed to "target" nanomaterials to specific or over-expressed receptors in diseased cells, and these typically involve The potential of targeting nanomedicines has already been illustrated in practice [5] [6] [7] . Among these general approaches, the role of nanomedicines exploiting active targeting via specific ligands is increasing in prominence [8] [9] [10] . These efforts have met with varying success [5] [6] [7] , and it is not always possible to fully explain the different outcomes. Likely, there are several reasons for this 2, 9, 11, 12 , but certainly there remains a lack of detailed mechanistic information on the link between nanoparticle surface and biological interactions.
Nanoparticles enter most cells by energy dependent processes, some of which not yet fully clarified 13, 14 . One potential objective of actively targeted nanomedicines is the design of a particle truly specific to a given cell, and which engages only with a specific cellular pathway.
Thus, while many nanoparticles enter most cells easily, the overall targeting success depends on the degree of discrimination in nanoparticle uptake; that is, the degree to which nanoparticles are taken up via relevant pathways, and not others. The detailed (in situ) structure of the nanoparticle interface with the entire biological environment (both target and biological milieu) is critical in determining this outcome. Here we present methods to evaluate that interface, with serum-rich conditions employed as more representative of in vivo studies. For the case of transferrin-targeted particles, some nanoparticle types fail to target the relevant pathway, even though they enter cells efficiently. Furthermore, even nanoparticles that target the relevant pathway may lose that specificity in the presence of a relevant biological milieu. This suggests the future need to design and characterize the nanoparticle-corona interface in more sophisticated ways.
While it is clear that nanoparticle size and shape are key factors for uptake [15] [16] [17] , current targeting strategies also involve conjugation of biofunctional moieties to nanoparticles in an effort to determine the biological outcomes 1, 2, 9, 12, [18] [19] [20] . In some cases this seems successful, 3 but in others less so (for example targeting moieties can hinder biological barrier   penetration   8,11 ). Practical problems include the fact that surface-grafting of biofunctional moieties may disrupt protein structure and function 21, 22 , or constrain its orientation.
Polyethylene glycol (PEG) spacers are expected to preserve protein function by moving the targeting moiety from the surface, provide flexibility 23 , and reduce non-specific binding of environmental biomolecules
24
.
As an illustrative example, cancer cell metabolism of iron may lead to over-expression of transferrin receptor (TfR) 25 , making transferrin (Tf, a glycoprotein of 79 kDa that binds TfR at extracellular pH, K d = 1-100 nM) 26 , a potential targeting molecule. Previous investigations with Tf-targeted nanoparticles have, sometimes, appeared inconsistent, and problems such as linker stability and protein flexibility have been identified [27] [28] [29] [30] .
Here fluorescent silica nanoparticles (SiO 2 , 50nm) are prepared by co-condensation of found optimal for TfR-mediated uptake (Scheme 1b). Nanoconjugates where Tf is directly coupled at the surface are also prepared. Nanoparticle characterization suggests well defined dispersions after Tf-functionalization for some of these particles (Table 1 and   Supplementary Table S1 ) and immuno dot-blots show recognition of the grafted Tf by anti-Tf antibodies ( Supplementary Fig. S1a ). While circular dichroism (CD) indicates that Tf structure is largely preserved ( Supplementary Fig. S1b ), we stress that this alone does not guarantee functional binding, suggesting the need for some of the methods outlined in this paper.
Thus, Differential Centrifugal Sedimentation (DCS) is used to study binding isotherms of nanoparticles to a soluble TfR fragment with preserved functionality. Unlike more conventional light scattering studies, this allows binding to be studied in a wide range of relevant environments. In parallel, RNA interference is used to silence, in this case, the expression of TfR in A549 lung epithelial cells and determine its effect on nanoparticle uptake. We emphasize that the absolute uptake level does not give information on the specificity of these interactions. However, the difference in particle uptake in silenced and non-silenced cells is indicative of the relative contribution made by that pathway.
Supplementary Figure S2 shows that in TfR-silenced cells residual TfR is small, and Tf uptake is essentially absent. This silenced cell model is now used to determine the contribution of Tf in the uptake of different nanoparticles.
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As a first step, we use simple buffer or serum free medium to test the capacity of different Tfconjugated nanoparticles to be recognised by TfR. As shown in Supplementary Fig. S3a -d, for a number of nanoparticles with different design, uptake is present in all cases, but does not decrease after TfR silencing. Similarly, the apparent particle size by DCS does not change when the soluble TfR fragment is added ( Supplementary Fig. S3e ). This indicates absence of interactions of these particles with TfR, which is consistent with the conclusion that uptake is not mediated by TfR.
Optimal design is achieved with Tf-decorated silica nanoparticles with PEG 8 spacers (SiO 2 -PEG 8 -Tf, as illustrated in Scheme 1b). With these nanoparticles, the apparent particle size by DCS increases with increasing TfR amounts ( Fig. 1a-b) , and this is reversible in the presence of excess Tf ( Supplementary Fig. S4a ). This indicates that these nanoparticles are recognised by TfR and bind it, while in the presence of excess Tf, binding is lost due to competition of the free Tf molecules. Furthermore, titration with TfR suggests saturation of receptor binding, which is consistent with roughly 40% of nominal Tf binding sites per particle (Fig. 1b) . From these data, we can estimate that roughly 100 TfR molecules are required to saturate one nanoparticle. This is likely an upper limit, because not all of these sites may be accessible on the cell surface. Nevertheless, the potential for multiple receptor binding may be reflected in co-operativity in cellular uptake.
When cells are exposed to these functional Tf-conjugated nanoparticles, confocal imaging shows colocalization of some of the particles with TfR (Fig. 1c) . Uptake in TfR-silenced cells is strongly reduced (Fig. 1d) . Similarly nanoparticle uptake decreases in the presence of increasing amounts of free Tf, though these competition experiments are less definitive due to potential for non-specific binding of the free Tf to the nanoparticles ( Supplementary Fig.   S4b ).
Overall, this indicates that these nanoparticles are internalised via TfR. Still, silencing also
shows that a portion of uptake does not depend on TfR, and this is consistent with the limited colocalization with TfR observed in Fig.1c . Nanoparticle export 31 appears absent ( Fig.1e) , at least for time scales comparable to Tf export (shown in Supplementary Fig. S2d ), and nanoparticles accumulate in the lysosomes (Fig. 1e) .
A variety of other particles with PEG 8 -linker has also been examined. Though the efficiency of internalization and uptake kinetics are affected by PEG densities and other details, in all cases the PEG of this size allows us to obtain functional Tf-conjugated nanoparticles internalized via TfR ( Supplementary Fig. S5 ).
As additional examples, we also show that particles with human Tf directly grafted on their surface (Fig. 2a) show little or no interactions with human TfR by DCS (Fig. 2b ) and, similarly, no reduction of uptake in TfR-silenced cells (Fig. 2c) . Similar results are obtained for analogues of the SiO 2 -PEG 8 -Tf particles with bovine Tf (SiO 2 -PEG 8 -bTf in Fig.2e-f ).
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Uptake of the pegylated particles without functionalization is higher than for Tf-particles, but does not depend on TfR ( Fig. 2d and 2f ). The actual uptake mechanism of pegylated particles (here as negative controls) is still under discussion 32 , but overall these results illustrate that the absolute uptake level is of little value in determining the specificity of nanoparticle-cell interactions. Nanoparticle design needs to be optimised in order to achieve recognition by the targeted receptors and approaches such as the one presented can be used to determine whether targeting is achieved.
All the results presented so far are obtained in buffer or serum free medium. A second step is to verify whether targeting is preserved in more realistic biological environments. To probe this question, we have performed similar studies in foetal bovine serum (FBS), though in principle one can use any relevant biological milieu. As serum concentration increases, DCS and immuno dot-blots show that the interaction of the nanoparticles with TfR decreases, ultimately becoming negligible ( Fig. 3a-b and Supplementary Fig. S6a ). On cells, addition of serum decreases the overall uptake, but, more significantly, the fraction of uptake that depends on TfR also decreases ( Fig. 3c and Supplementary Fig. S6b ), suggesting that the particles entirely lose their specificity (as illustrated in Fig. 3d ). The study in FBS is of interest because endogenous bovine Tf has significantly lower affinity for human TfR, and competes much less with the human Tf-grafted particles. We can confirm that loss of targeting occurs also in human serum ( Supplementary Fig. S7-S9 ). Furthermore, we can eliminate the competition of free Tf, and show that both in Tf-depleted and non-depleted human serum targeting is lost ( Supplementary Fig. S9 ). Tf depletion is repeated until there is no residual Tf, while preserving the general serum composition ( Supplementary Fig. S7-8 ). Collectively these results suggest that, with increasing serum concentration (whether it contains competing free Tf or not) the targeting capacity of Tf-particles is lost.
To further clarify this, nanoparticles are exposed to serum and isolated as described previously 33 to investigate whether there is a contribution of particle-serum binding (termed 'hard corona' because of its durability) in these observations. Indeed, for pegylated and pegylated Tf-functionalized nanoparticles protein binding is observed, though much less than for the non-pegylated particles ( Supplementary Fig. S6c and S10).
A range of Tf-functionalized PEG 8 -particles further modified with secondary PEG on the particle surface or directly on Tf has also been also prepared, in an attempt at controlling unspecific protein binding (see Supplementary Methods for details). In all cases, however, the targeting specificity is lost upon exposure to biological serum ( Supplementary Fig. S11 ).
In conclusion, nanoparticle grafting of targeting molecules (even where the protein remains functional) does not simply imply bio-recognition by corresponding receptors. More significantly, when targeting is achieved in simple dispersions, such as PBS, this can be lost in relevant physiological conditions. Also, besides the absolute uptake, a most critical feature 6 is the capacity of the nanoparticles to discriminate between different targets, particularly in the complex biological milieu in which they are applied. In practice, failure to achieve this may allow accumulation not only in target cells, but also in cells that do not exhibit any pathology, not intended to be targeted.
In future, it seems necessary to carry out binding and cell-level studies in a variety of biological fluids in which the particles will be applied. Success in similar systems by no means implies success in vivo, but if targeting is not observed in relevant fluids, apparent targeting in vivo may be a consequence of other poorly understood phenomena. Indeed, we may generalize these comments, beyond the focus of these experiments, since binding to cells or tissue components (rather than uptake) may be sufficient prior to thermal ablation 34, 35 or other therapeutic strategies. Such cases also could benefit from a comparable in situ binding analysis as discussed here.
Though these studies focus on a single receptor, the mechanisms involved are of general nature, and suggest the need to mechanistically link ligand-targeting to specific biological outcomes. The approaches outlined here may be of general value in such studies, and possibly shed some light on factors rendering some targeting studies more promising than others [5] [6] [7] .
Methods

Particle Characterization and Differential Centrifugal Sedimentation
Detailed methods for particle synthesis are reported in Supplementary Information.
Nanoparticle hydrodynamic diameter and zeta potential were measured on a Malvern Nanosizer ZS. Size measurements are averaged results from 3x11 runs at 25 °C. Zeta potential experiments are averaged from 2 runs of between 10 and 100 scans at 25 °C.
Differential centrifugal sedimentation (DCS) experiments were performed with a CPS Disc
Centrifuge DC24000 (CPS instruments). For the titration, 0.5 mg/ml SiO 2 nanoparticles in phosphate buffer saline (PBS) were incubated with varying concentrations of TfR for 1 hour at room temperature (RT) prior to measurement. A recombinant soluble fragment of the full human TfR, produced from a mouse myeloma cell line (NSO-derived) was used (R&D Systems). This corresponds to the extracellular domain Cys89-Phe760, which has been shown to remain active as a soluble fragment, and includes the Tf-binding region 569-760. In case of the reversed receptor binding, nanoparticles incubated with the receptor were subsequently incubated with excess free Tf (250 µg/ml) for 1 hour at RT, prior measurement.
For the measurements in-situ, 0.5 mg/ml SiO 2 nanoparticles were dispersed in 10 % and 55 % serum (in PBS) and incubated with 20 μg/ml TfR for 1 hour at RT. The total volume of injected sample in each run was 0.4 ml.
Immuno Dot-blots
The immuno dot-blots were prepared by spotting mouse monoclonal antibodies against TfR, Tf, or HSA (human serum albumin) (Abcam -ab9179, ab769, ab10241, respectively) on polyvinylidene fluoride (PVDF) membranes (1 µl at 100, 20 and 10 µg/ml). The blots were blocked in 5 % skimmed milk in PBS for 1 hour at RT, washed 3 times (10 minutes each) in PBS, and incubated with 0.04 mg/ml nanoparticles in PBS for 1 hour at RT. Blots were washed 3 times for 10 minutes, dried and scanned for fluorescence using TYPHOON 9200
imager.
Cell Culture
Tissue culture reagents were purchased from GIBCO Invitrogen Corporation/Life
Technologies Life Sciences (Carlsbad, CA) unless otherwise specified. A549 cells (ATCC-CCL-185) were maintained as monolayer cultures in MEM supplemented with 10% foetal bovine serum (FBS), at 37 ˚C and 5 % CO 2 (cMEM). 
Cell Silencing and Flow Cytometry
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